Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Deepak Bhatt acquired deferred share units in Bristol-Myers Squibb, convertible to common stock upon leaving the board or at a specified future date.

Summary

• On March 31, 2024, Deepak Bhatt, a director of Bristol-Myers Squibb, acquired deferred share units.
• These units, convertible to common stock, become settleable upon cessation of directorship or at a previously specified future date.
• The transaction involved 161.35 deferred share units at a price of $54.23 per unit.
• Following the transaction, Bhatt beneficially owns 10,050.37 shares of common stock, including deferred compensation and reinvested dividends.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, which is generally seen as a sign of confidence. However, it's a routine transaction related to compensation.

Positives

• The acquisition of deferred share units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan provides a mechanism for directors to accumulate company stock over time.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Comparison to Industry Standards

• Director compensation packages often include deferred share units to align director interests with shareholder value, a common practice among large pharmaceutical companies.
• Companies like Pfizer (PFE) and Merck (MRK) also utilize similar deferred compensation plans for their non-employee directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates